MedPath

Outpatient Lung Impedance-Guided Preventive Therapy in Patients With Chronic Heart Failure (CHF)

Phase 3
Conditions
Chronic Congestive Heart Failure
Interventions
Other: Lung impedence-guided treatment
Registration Number
NCT01315223
Lead Sponsor
Hillel Yaffe Medical Center
Brief Summary

Patients suffering from Chronic Heart Failure (CHF) are hospitalized for acute heart failure (AHF) several times a year. Currently, we have no method for prediction of future developments of AHF. In our center we have investigated the monitoring of lung impedence as a predictor for future deterioration. It was found that a decrease in lung impedence of more than 15% from normal value predicts AHF development with sensitivity of 98%. In this study we try to prove the hypothesis that preventive treatment according to lung impedence value may prevent future hospitalizations for AHF and improve clinical outcome.

Patients recruited by year:

2011 - 50; 2012 - 25; 2013 - 35; 2014 - 30; 2015 - 50; 2016 - 5

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Patients suffering from CHF, NYHA II-IV class
  • LV lower than 35% to LV lower than 45%
Exclusion Criteria
  • Patients with additional disease with life-expectancy of less than 2 years

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lung impedence-guided treatmentLung impedence-guided treatment-
Primary Outcome Measures
NameTimeMethod
Reduction of hospitalization for acute heart failureFive years
Secondary Outcome Measures
NameTimeMethod
Improved clinical outcome for CHF patientsFive years

Trial Locations

Locations (1)

Hillel Yaffe Medical Center

🇮🇱

Hadera, Israel

© Copyright 2025. All Rights Reserved by MedPath